INSMED Business Summary

Insmed Inc. is a global biopharmaceutical company specializing in the development and commercialization of therapies for rare respiratory and infectious diseases. The company generates revenue primarily through the specialty drug sales of its commercial portfolio, led by ARIKAYCE (amikacin liposome inhalation suspension) for refractory Mycobacterium avium complex (MAC) lung disease and the recently launched BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis (NCFB). Its business is segmented into Respiratory, Immunology & Inflammation, and Neuro & Other Rare therapeutic areas, with a heavy focus on high-margin orphan drug pricing and specialty pharmacy distribution. Within the competitive landscape, Insmed contends with large-cap pharmaceutical firms and biotech peers such as Takeda Pharmaceutical, argenx, and Teva Pharmaceutical; however, it maintains a dominant market position as a pioneer in inhaled therapies for neutrophil-driven pulmonary conditions, particularly following the successful 2025-2026 global rollout of brensocatib. The company is led by Chair and CEO William H. Lewis, who joined in 2012 and previously served as President and CFO of Aegerion Pharmaceuticals, where he was instrumental in pivoting the firm toward rare diseases. The executive team includes CFO Sara M. Bonstein, who brought over 20 years of experience from Eli Lilly and Johnson & Johnson, and COO Roger Adsett, a veteran with three decades of industry expertise. Insmed’s strategic direction is further guided by a high-profile Board of Directors, featuring Lead Independent Director David R. Brennan, the former CEO of AstraZeneca, and Elizabeth McKee Anderson, a former executive at Janssen (Johnson & Johnson). This leadership group has successfully transitioned Insmed from a clinical-stage entity into a commercial powerhouse, targeting cash-flow positivity by 2027 through aggressive pipeline expansion and international market penetration.